https://scholars.lib.ntu.edu.tw/handle/123456789/637872
標題: | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial | 作者: | Rha, Sun Young Oh, Do-Youn Yañez, Patricio Bai, Yuxian Ryu, Min-Hee Lee, Jeeyun Rivera, Fernando Alves, Gustavo Vasconcelos Garrido, Marcelo Shiu, Kai-Keen Fernández, Manuel González Li, Jin Lowery, Maeve A Çil, Timuçin Cruz, Felipe Melo Qin, Shukui Luo, Suxia Pan, Hongming Wainberg, Zev A Yin, Lina Bordia, Sonal Bhagia, Pooja Wyrwicz, Lucjan S KUN-HUEI YEH |
公開日期: | 十一月-2023 | 卷: | 24 | 期: | 11 | 來源出版物: | The Lancet. Oncology | 摘要: | PD-1 inhibitors combined with chemotherapy have shown efficacy in gastric or gastro-esophageal junction cancer. We compared the efficacy and safety of pembrolizumab plus chemotherapy with placebo plus chemotherapy in participants with locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/637872 | ISSN: | 14702045 | DOI: | 10.1016/S1470-2045(23)00515-6 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。